Noticias y vídeos - BAVARIAN NORNAM.DK 10

Recommendation of first chikungunya vaccine for persons as young as 12 years old expands access for US travelers to regions with outbreak or elevated risk of chikungunya. COPENHAGEN, Denmark, April 16, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the virus-like particle (VLP)-based, single-dose vaccine, VIMKUNYA™ (Chikungunya Vaccine,...

COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors’ proposal to transfer the Company’s result to 2025 was also adopted. The Remuneration Report for 2024 was not approved. It is noted that this was an indicative vote, and that the decision will not entail consequences on the reported remuneration. The Board of Directors will discuss the decision,...

COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors’ proposal to transfer the Company’s result to 2025 was also adopted. The Remuneration Report for 2024 was not approved. It is noted that this was an indicative vote, and that the decision will not entail consequences on the reported remuneration. The Board of Directors will discuss the decision,...

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ® (Smallpox and Mpox Vaccine, Live, Non-replicating) for prevention of smallpox and mpox disease in adults 18 years of age and older. This approval will provide additional flexibility for stockpiling against a smallpox event or mpox outbreak. The approval follows a standard review with the FDA of a...

COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Wednesday, 9 April 2025, at 4 PM CEST at Comwell Borupgaard, Nørrevej 80, DK-3070 Snekkersten, Denmark with the following agenda: The Board of Directors' report on the Company's activities in the past year. Presentation of the Annual Report for adoption. A proposal from the Board of Directors...

COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523. The transactions relate to the award and vesting of restricted stock units (RSUs)...

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced. COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2024. The consolidated, audited results were in line with the preliminary results announced on February 3, 2025. The full report is attached as a PDF file and can be found on the Company's website,...

First chikungunya vaccine approved in Europe for persons as young as 12 years old. On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA ® for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older. The virus-like particle (VLP) single-dose...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers. On track for commercial launch in the U.S. in the first half of 2025. A Tropical Disease Priority Review Voucher was awarded to the Company upon approval. COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine,...

Travel Health business demonstrated strong growth of 22%. Additional mpox vaccine orders during outbreak drove higher revenues for the Public Preparedness business and also secured a strong foundation for 2025. Financial guidance for 2025 in line with the Company’s 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2024 and provided its financial guidance for 2025. The preliminary revenue...

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure and meeting the long-term obligations relating to the Company’s share-based incentive programs for the Board...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in the first half of 2025, pending final marketing authorization. COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending...

COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052,...

COPENHAGEN, Denmark, January 20, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052,...

COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million as announced on December 11, 2024 . The decision to launch the program is driven by a better-than-expected performance and improved visibility pertaining to the Company’s Travel Health business, with synergies from a number of recent and near-term expected events as described in the December 11 announcement. Bavarian Nordic will hold the...

COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Paul Chaplin 2. Reason for the notification a) Position/status President and Chief Executive Officer of Bavarian...

COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a new long-term incentive program for Executive Management and selected employees in the Bavarian Nordic Group. Members of the Executive Management are granted a mix of performance restricted stock units (Performance RSUs) and warrants, both subject to the successful achievement of relevant Key Performance Indicators (KPI’s). Employees participating in...

COPENHAGEN, Denmark, December 11, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a share buy-back program of up to DKK 150 million in the first quarter of 2025. This decision should be viewed in the context of improved visibility around the Company’s Travel Health business, driven by a number of completed and near-term expected events, including: A better-than-expected performance of the Travel Health business, as demonstrated by the recent guidance upgrade. The...

COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. The transaction concerns the exercise of warrants by Thomas Bennekov, who has served as an employee-elected member of the Board of Directors of Bavarian Nordic since April 2021. The warrants were awarded to Mr....

COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 218,750 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. A total of 21,875 new shares were subscribed for in cash at DKK 146.60 per share of nominally DKK 10. The total proceeds to Bavarian Nordic A/S from the...